Samsung Biologics Secures 97.98% of Polypeptide Group in Tender Offer

Requirements for Compulsory Acquisition Met
"Acquisition to Be Completed by Year-End or in Q1 2027 After Regulatory Approvals"

Samsung Biologics has secured a 97.98% stake in its tender offer for global peptide contract development and manufacturing organization (CDMO) Polypeptide Group.

Samsung Biologics said on November 2 that a total of 32,350,302 shares had been tendered in the preliminary final results of its tender offer for Polypeptide Group. This represents 97.98% of the shares targeted for purchase, exceeding both the minimum acceptance condition of 66.7% and the 90% threshold required to compulsorily acquire the remaining shares held by minority shareholders. The final results will be announced on November 5, following verification by an independent auditor.

Corporate logos of Samsung Biologics and Polypeptide Group, from left. Samsung Biologics.

The tender offer was conducted through Samsung Peptide, a special-purpose company (SPC) subsidiary established for the acquisition. It offered 44.31 Swiss francs (approximately KRW 71,800) per share for 33,016,411 issued shares, excluding treasury shares.

Samsung Biologics plans to secure 100% ownership by compulsorily acquiring the remaining shares held by minority shareholders. The transaction is expected to close after obtaining regulatory approvals from the relevant authorities in Europe, India, Australia and Brazil. The acquisition is expected to be completed at the end of 2026 or in the first quarter of 2027.

Samsung Biologics signed an acquisition agreement with Polypeptide Group in July. The purchase price was 1.46 billion Swiss francs, equivalent to approximately KRW 2.7 trillion at the exchange rate at the time.

With this acquisition, Samsung Biologics will expand its CDMO business beyond its existing antibody drugs, messenger RNA (mRNA) and antibody-drug conjugates (ADCs) to include peptides. The company plans to diversify its portfolio and strengthen its medium- to long-term growth drivers by securing peptide development and manufacturing capabilities.

This content was produced with the assistance of AI translation services.